fexofenadine has been researched along with cp 100356 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chupka, J; Feng, B; Fenner, KS; Frederick, KS; Kalgutkar, AS; Kempshall, S; Mireles, RJ; Troutman, MD | 1 |
1 other study(ies) available for fexofenadine and cp 100356
| Article | Year |
|---|---|
N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.
Topics: Animals; Anti-Allergic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Carrier Proteins; CHO Cells; Cricetinae; Cricetulus; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estradiol; Hypnotics and Sedatives; Intestinal Absorption; Isoquinolines; Male; Midazolam; Pharmaceutical Preparations; Prazosin; Quinazolines; Rats; Rats, Sprague-Dawley; Sympatholytics; Terfenadine | 2009 |